Pancreatic Cancer

Itraconazole has retrospective-combination relevance in recurrent pancreatic cancer, where standard treatment options are often limited.

Overview

The main interest here is not standalone activity, but whether itraconazole can add useful pathway pressure when combined with chemotherapy.

Key human data

• A retrospective study used 400 mg daily for four days, repeated every two weeks, with chemotherapy

• Overall survival was reported as significantly improved compared with chemotherapy alone

Practical interpretation

This is still an early and non-definitive signal, but it is strong enough to justify pancreatic cancer as a real page in the topic.

References

Repurposing itraconazole for the treatment of cancer
https://pmc.ncbi.nlm.nih.gov/articles/PMC6769799/